, Volume 71, Issue 2, pp 635–646 | Cite as

Vildagliptine protects SH-SY5Y human neuron-like cells from Aβ 1–42 induced toxicity, in vitro

  • Alim Hüseyin DokumacıEmail author
  • Mukerrem Betul Yerer Aycan


The amyloid β (Aβ) toxic fibrils is thought to play a central role in the onset and progression of Alzheimer’s disease (AD) because of it is a main formation of senile plaques. Diabetic patients are more vulnerable to caught Alzheimer’s disease. Vildagliptine, a novel anti diabetic agent, has been reported to exert protective effects on AD rat models in restricted study. We aimed to investigate any protective effects of vildagliptine against Aβ fibrils on SH-SY5Y cell line. Vildagliptine decreased PSEN1 and PSEN2 mRNA levels which enroll Aβ production. In addition, vildagliptin was downregulated caspase-3 and caspase-9 expression levels which were evoked by Aβ. Also we confirmed cellular viability with real time cell analyzer and MTT assay. Our data exposed that vildagliptine has lowering effect on GSK3β and Tau phosphorylation. However we did not get protective effect of vildagliptine against Aβ toxicity on mitochondrial membrane potential. These results indicate that vildagliptine exerts a protective effect against Aβ by decreasing apoptosis related proteins, lowering GSK3β and Tau phosphorylation levels in addition to expression of PSEN1 and PSEN2 mRNA downregulation effect.


Cell viability Vildagliptine Amyloid beta Apoptosis Memantine 



Alzheimer’s disease


Amyloid beta






Glycogen synthase kinase 3 beta


Amyloid precursor protein


Presenilin 1





Funding was provided by Erciyes Üniversitesi (Grant No. TDK-5824).


  1. Agholme L, Lindström T, Kågedal K, Marcusson J, Hallbeck M (2010) An in vitro model for neuroscience: differentiation of SH-SY5Y cells into cells with morphological and biochemical characteristics of mature neurons. J Alzheimer’s Dis 20:1069–1082CrossRefGoogle Scholar
  2. Al-Mousa F, Michelangeli F (2012) Some commonly used brominated flame retardants cause Ca2 + -ATPase inhibition, beta-amyloid peptide release and apoptosis in SH-SY5Y neuronal cells. PLoS ONE 7:e33059CrossRefGoogle Scholar
  3. Anand R, Gill KD, Mahdi AA (2014) Therapeutics of Alzheimer’s disease: past, present and future. Neuropharmacology 76:27–50. CrossRefGoogle Scholar
  4. Atrakchi-Baranes D et al (2017) Combination therapy of type 2 diabetes medications as a treatment target for alzheimer disease. Alzheimer’s Demen J Alzheimer’s Assoc 13:P648CrossRefGoogle Scholar
  5. Awasthi A, Matsunaga Y, Yamada T (2005) Amyloid-beta causes apoptosis of neuronal cells via caspase cascade, which can be prevented by amyloid-beta-derived short peptides. Exp Neurol 196:282–289CrossRefGoogle Scholar
  6. Carvalho C, Santos MS, Oliveira CR, Moreira PI (2015) Alzheimer’s disease and type 2 diabetes-related alterations in brain mitochondria, autophagy and synaptic markers. Biochim Biophys Acta (BBA) Mol Basis Dis 1852:1665–1675CrossRefGoogle Scholar
  7. Cormier KW, Woodgett JR (2017) Recent advances in understanding the cellular roles of GSK-3. F1000Res 6:167CrossRefGoogle Scholar
  8. Craft S (2006) Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Dis 20:298–301. CrossRefGoogle Scholar
  9. Dahlgren KN, Manelli AM, Stine WB, Baker LK, Krafft GA, LaDu MJ (2002) Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J Biol Chem 277:32046–32053CrossRefGoogle Scholar
  10. De Felice FG, Ferreira ST (2014) Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 63:2262–2272CrossRefGoogle Scholar
  11. de la Monte SM, Wands JR (2008) Alzheimer’s disease is type 3 diabetes—evidence reviewed. J Diabetes Sci Technol 2:1101–1113CrossRefGoogle Scholar
  12. Dei Cas A et al (2017) Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes. Cardiovasc Diabetol 16:27CrossRefGoogle Scholar
  13. Eckert A, Keil U, Marques CA, Bonert A, Frey C, Schüssel K, Müller WE (2003) Mitochondrial dysfunction, apoptotic cell death, and Alzheimer’s disease. Biochem Pharmacol 66:1627–1634CrossRefGoogle Scholar
  14. Fosgerau K, Hoffmann T (2015) Peptide therapeutics: current status and future directions. Drug Discov Today 20:122–128CrossRefGoogle Scholar
  15. Green DR, Reed JC (1998) Mitochondria and apoptosis. Science 281:1309–1312CrossRefGoogle Scholar
  16. Haan MN (2006) Therapy insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer’s disease. Nat Clin Pract Neurol 2:159–166CrossRefGoogle Scholar
  17. Hakem R et al (1998) Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell 94:339–352CrossRefGoogle Scholar
  18. Hernandez F, Lucas JJ, Avila J (2013) GSK3 and tau: two convergence points in Alzheimer’s disease. J Alzheimer’s Dis 33:S141–S144CrossRefGoogle Scholar
  19. Huang T-J, Verkhratsky A, Fernyhough P (2005) Insulin enhances mitochondrial inner membrane potential and increases ATP levels through phosphoinositide 3-kinase in adult sensory neurons. Mol Cell Neurosci 28:42–54CrossRefGoogle Scholar
  20. Jan A et al (2011) Aβ42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Aβ42 species. J Biol Chem 286:8585–8596CrossRefGoogle Scholar
  21. Jantas D, Szymanska M, Budziszewska B, Lason W (2009) An involvement of BDNF and PI3-K/Akt in the anti-apoptotic effect of memantine on staurosporine-evoked cell death in primary cortical neurons. Apoptosis 14:900–912CrossRefGoogle Scholar
  22. Ke N, Wang X, Xu X, Abassi YA (2011) The xCELLigence system for real-time and label-free monitoring of cell viability. Met Mol Biol 740:33–43CrossRefGoogle Scholar
  23. Kosaraju J et al (2013a) Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer’s disease. Neuropharmacology 72:291–300CrossRefGoogle Scholar
  24. Kosaraju J, Murthy V, Khatwal RB, Dubala A, Chinni S, Muthureddy Nataraj SK, Basavan D (2013b) Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer’s disease. J Pharm Pharmacol 65:1773–1784CrossRefGoogle Scholar
  25. Krajewski S et al (1999) Release of caspase-9 from mitochondria during neuronal apoptosis and cerebral ischemia. Proc Natl Acad Sci 96:5752–5757CrossRefGoogle Scholar
  26. Kuhla B, Loske C, De Arriba SG, Schinzel R, Huber J, Münch G (2004) Differential effects of “advanced glycation endproducts” and β-amyloid peptide on glucose utilization and ATP levels in the neuronal cell line SH-SY5Y. J Neural Transm 111:427–439CrossRefGoogle Scholar
  27. Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K (2004) Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett 566:261–269CrossRefGoogle Scholar
  28. Lopes FM et al (2010) Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies. Brain Res 1337:85–94CrossRefGoogle Scholar
  29. Lopez-Toledano MA, Shelanski ML (2007) Increased neurogenesis in young transgenic mice overexpressing human APP Sw Ind. J Alzheimer’s Dis 12:229–240CrossRefGoogle Scholar
  30. Lorenzo A, Yankner BA (1994) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci 91:12243–12247CrossRefGoogle Scholar
  31. Luchsinger JA, Tang M-X, Stern Y, Shea S, Mayeux R (2001) Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154:635–641CrossRefGoogle Scholar
  32. Mansoor S, Gupta N, Luczy-Bachman G, Limb GA, Kuppermann BD, Kenney MC (2010) Protective effects of memantine and epicatechin on catechol-induced toxicity on Müller cells in vitro. Toxicology 271:107–114CrossRefGoogle Scholar
  33. Mehmet H (2000) Apoptosis: caspases find a new place to hide. Nature 403:29CrossRefGoogle Scholar
  34. Pap M, Cooper GM (1998) Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 273:19929–19932CrossRefGoogle Scholar
  35. Park MH et al (2012) Mutant presenilin 2 increases β-secretase activity through reactive oxygen species-dependent activation of extracellular signal-regulated kinase. J Neuropathol Exp Neurol 71:130–139CrossRefGoogle Scholar
  36. Pintana H, Apaijai N, Chattipakorn N, Chattipakorn SC (2013) DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats. J Endocrinol 218:1–11CrossRefGoogle Scholar
  37. Pipatpiboon N, Pintana H, Pratchayasakul W, Chattipakorn N, Chattipakorn SC (2013) DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption. Eur J Neurosci 37:839–849CrossRefGoogle Scholar
  38. Ponce-Lopez T, Liy-Salmeron G, Hong E, Meneses A (2011) Lithium, phenserine, memantine and pioglitazone reverse memory deficit and restore phospho-GSK3β decreased in hippocampus in intracerebroventricular streptozotocin induced memory deficit model. Brain Res 1426:73–85CrossRefGoogle Scholar
  39. Prasad-Reddy L, Isaacs D (2015) A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context.
  40. Reitz C, Mayeux R (2014) Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol 88:640–651CrossRefGoogle Scholar
  41. Rhein V, Baysang G, Rao S, Meier F, Bonert A, Müller-Spahn F, Eckert A (2009) Amyloid-beta leads to impaired cellular respiration, energy production and mitochondrial electron chain complex activities in human neuroblastoma cells. Cell Mol Neurobiol 29:1063CrossRefGoogle Scholar
  42. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM (2005) Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer’s disease: link to brain reductions in acetylcholine. J Alzheimers Dis 8:247–268CrossRefGoogle Scholar
  43. Ryman D, Lamb BT (2006) Genetic and environmental modifiers of Alzheimer’s disease phenotypes in the mouse. Curr Alzheimer Res 3:465–473CrossRefGoogle Scholar
  44. Sadeghi A, Hami J, Razavi S, Esfandiary E, Hejazi Z (2016) The effect of diabetes mellitus on apoptosis in hippocampus: cellular and molecular aspects. Int J Prev Med 7:57CrossRefGoogle Scholar
  45. Scheen AJ (2010) Dipeptidylpeptidase-4 inhibitors (gliptins). Clin Pharmacokinet 49:573–588CrossRefGoogle Scholar
  46. Seoposengwe K, Van Tonder JJ, Steenkamp V (2013) In vitro neuroprotective potential of four medicinal plants against rotenone-induced toxicity in SH-SY5Y neuroblastoma cells. BMC Complement Altern Med 13:353CrossRefGoogle Scholar
  47. Spires-Jones TL, Hyman BT (2014) The intersection of amyloid beta and tau at synapses in Alzheimer’s disease. Neuron 82:756–771CrossRefGoogle Scholar
  48. Steen E et al (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease—is this type 3 diabetes? J Alzheimers Dis 7:63–80CrossRefGoogle Scholar
  49. Susin SA et al (1999) Mitochondrial release of caspase-2 and-9 during the apoptotic process. J Exp Med 189:381–394CrossRefGoogle Scholar
  50. Tarozzi A et al (2008) Cyanidin 3-O-glucopyranoside protects and rescues SH-SY5Y cells against amyloid-beta peptide-induced toxicity. NeuroReport 19:1483–1486CrossRefGoogle Scholar
  51. Tasci I et al (2013) Cognitive and functional influences of vildagliptin, a DPP-4 inhibitor, added to ongoing metformin therapy in elderly with type 2 diabetes. Endocr Metab Immune Disord Drug Targ (Former Curr Drug Targ Immune Endocr Metab Disord) 13:256–263Google Scholar
  52. Tenneti L, Lipton SA (2000) Involvement of activated caspase-3-like proteases in N-methyl-D-aspartate-induced apoptosis in cerebrocortical neurons. J Neurochem 74:134–142CrossRefGoogle Scholar
  53. Williamson J, Goldman J, Marder KS (2009) Genetic aspects of Alzheimer disease. The neurologist 15:80CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Department of PharmacologyErciyes University Faculty of PharmacyKayseriTurkey

Personalised recommendations